Presentation Preview: Preclinical Evaluation of SLV-013: A Novel GPC1- Targeting ADC for the Treatment of Solid Tumors
- Providing the strategic rationale for targeting GPC-1, overall biology and comprehensive expression profiling across multiple cancer lineages and primary normal cells and tissues
- Developing GPC-1 targeting ADCs, utilizing a proprietary hydrophilic and highly stable linker technology
- Unveiling the preclinical characterization of SLV-013, including the cell binding, internalization, and in vitro and in vivo efficacy data